Combination strategies for advanced-stage urothelial carcinoma: a paradigm shift

IF 81.1 1区医学 Q1 ONCOLOGY

Nature Reviews Clinical Oncology Pub Date : 2024-01-26 DOI:10.1038/s41571-024-00861-7

Nimira Alimohamed, Srikala S. Sridhar

引用次数: 0

Abstract

Durable responses with first-line platinum-based chemotherapy for advanced-stage urothelial carcinoma are rare, and patient outcomes are poor. Recently, CheckMate 901 became the first phase III trial to establish a significant overall survival benefit from a combined chemoimmunotherapy approach in this disease setting. Herein, we discuss key findings from CheckMate 901 and their implications in the context of a rapidly evolving treatment landscape.

查看原文本刊更多论文

晚期尿路上皮癌的联合治疗策略：范式转变。

晚期尿路上皮癌一线铂类化疗的持久疗效非常罕见，患者的预后也很差。最近，CheckMate 901 成为首个在这种疾病背景下证实联合化疗免疫疗法能显著延长总生存期的 III 期试验。在此，我们将讨论 CheckMate 901 的主要发现及其在快速发展的治疗环境中的意义。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Clinical Oncology 医学-肿瘤学

CiteScore

99.40

自引率

0.40%

发文量

114

审稿时长

6-12 weeks

期刊介绍： Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.